Cargando…

Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus

Context: TangGanJian (TGJ) has a curative effect in the clinical treatment of nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM), while the mechanism involved in the treatment process remains unclear. Objective: This study details the mechanism of TGJ on the treatment of N...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Yanbo, Xiong, Wei, Li, Jingjing, Hu, Aimin, He, Zhiwei, Zhang, Jiawen, Zhou, Guoyun, Yin, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249541/
https://www.ncbi.nlm.nih.gov/pubmed/30460863
http://dx.doi.org/10.1080/13880209.2018.1504972
_version_ 1783372774116425728
author Fan, Yanbo
Xiong, Wei
Li, Jingjing
Hu, Aimin
He, Zhiwei
Zhang, Jiawen
Zhou, Guoyun
Yin, Qiang
author_facet Fan, Yanbo
Xiong, Wei
Li, Jingjing
Hu, Aimin
He, Zhiwei
Zhang, Jiawen
Zhou, Guoyun
Yin, Qiang
author_sort Fan, Yanbo
collection PubMed
description Context: TangGanJian (TGJ) has a curative effect in the clinical treatment of nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM), while the mechanism involved in the treatment process remains unclear. Objective: This study details the mechanism of TGJ on the treatment of NAFLD with T2DM. Materials and methods: NAFLD was induced in T2DM rat model. Male Wistar rats were assigned into six groups: Group I (control), Group II (model), Group III (pioglitazone, 0.5 mg/kg), Group IV (high dose of TGJ, 24.8 g/kg), Group V (middle dose of TGJ, 12.4 g/kg) and Group VI (low dose of TGJ, 6.2 g/kg). All rats in each group were treated with the corresponding drugs by gavage for 8 weeks. Haematoxylin and eosin analysis was conducted. The indicators of inflammatory and oxidative stress were analysed utilizing one-way ANOVA. Results: The contents of TNF-α (15.794 ± 3.302 pg/mL), IL-6 (76.801 ± 8.491 pg/mL), IL-1β (100.101 ± 13.150 pg/mL), CRP (1.052 ± 0.079 pg/mL) and MDA (3.972 ± 0.159 pg/mL) were obviously elevated in NAFLD with T2DM rats compared to controls. Except for the IL-6, the levels of other markers declined in a dose-dependent manner after treatment with TGJ. The SOD (14.139 ± 1.479 U/mgprot) and GSH-PX (81.511 ± 5.276 U/mgprot) levels significantly decreased in NAFLD with T2DM rats, while the levels of these indicators increased after treatment with TGJ. Conclusions: TGJ may be a therapy for the NAFLD with T2DM rats by modulating the inflammatory response and the oxidative stress capacity.
format Online
Article
Text
id pubmed-6249541
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-62495412018-11-26 Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus Fan, Yanbo Xiong, Wei Li, Jingjing Hu, Aimin He, Zhiwei Zhang, Jiawen Zhou, Guoyun Yin, Qiang Pharm Biol Research Article Context: TangGanJian (TGJ) has a curative effect in the clinical treatment of nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM), while the mechanism involved in the treatment process remains unclear. Objective: This study details the mechanism of TGJ on the treatment of NAFLD with T2DM. Materials and methods: NAFLD was induced in T2DM rat model. Male Wistar rats were assigned into six groups: Group I (control), Group II (model), Group III (pioglitazone, 0.5 mg/kg), Group IV (high dose of TGJ, 24.8 g/kg), Group V (middle dose of TGJ, 12.4 g/kg) and Group VI (low dose of TGJ, 6.2 g/kg). All rats in each group were treated with the corresponding drugs by gavage for 8 weeks. Haematoxylin and eosin analysis was conducted. The indicators of inflammatory and oxidative stress were analysed utilizing one-way ANOVA. Results: The contents of TNF-α (15.794 ± 3.302 pg/mL), IL-6 (76.801 ± 8.491 pg/mL), IL-1β (100.101 ± 13.150 pg/mL), CRP (1.052 ± 0.079 pg/mL) and MDA (3.972 ± 0.159 pg/mL) were obviously elevated in NAFLD with T2DM rats compared to controls. Except for the IL-6, the levels of other markers declined in a dose-dependent manner after treatment with TGJ. The SOD (14.139 ± 1.479 U/mgprot) and GSH-PX (81.511 ± 5.276 U/mgprot) levels significantly decreased in NAFLD with T2DM rats, while the levels of these indicators increased after treatment with TGJ. Conclusions: TGJ may be a therapy for the NAFLD with T2DM rats by modulating the inflammatory response and the oxidative stress capacity. Taylor & Francis 2018-11-21 /pmc/articles/PMC6249541/ /pubmed/30460863 http://dx.doi.org/10.1080/13880209.2018.1504972 Text en © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Fan, Yanbo
Xiong, Wei
Li, Jingjing
Hu, Aimin
He, Zhiwei
Zhang, Jiawen
Zhou, Guoyun
Yin, Qiang
Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus
title Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus
title_full Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus
title_fullStr Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus
title_full_unstemmed Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus
title_short Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus
title_sort mechanism of tangganjian on nonalcoholic fatty liver disease with type 2 diabetes mellitus
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249541/
https://www.ncbi.nlm.nih.gov/pubmed/30460863
http://dx.doi.org/10.1080/13880209.2018.1504972
work_keys_str_mv AT fanyanbo mechanismoftangganjianonnonalcoholicfattyliverdiseasewithtype2diabetesmellitus
AT xiongwei mechanismoftangganjianonnonalcoholicfattyliverdiseasewithtype2diabetesmellitus
AT lijingjing mechanismoftangganjianonnonalcoholicfattyliverdiseasewithtype2diabetesmellitus
AT huaimin mechanismoftangganjianonnonalcoholicfattyliverdiseasewithtype2diabetesmellitus
AT hezhiwei mechanismoftangganjianonnonalcoholicfattyliverdiseasewithtype2diabetesmellitus
AT zhangjiawen mechanismoftangganjianonnonalcoholicfattyliverdiseasewithtype2diabetesmellitus
AT zhouguoyun mechanismoftangganjianonnonalcoholicfattyliverdiseasewithtype2diabetesmellitus
AT yinqiang mechanismoftangganjianonnonalcoholicfattyliverdiseasewithtype2diabetesmellitus